10-K/APeriod: FY2023

BeOne Medicines Ltd. Annual Report (Amendment), Year Ended Dec 31, 2023

Filed January 8, 2025For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC) filed an Annual Report Amendment (10-K/A) on January 8, 2025, for the period ending December 31, 2023. This filing primarily pertains to the exhibits and financial statement schedules, specifically including the parent company's financial statements (Schedule I) for the years 2023, 2022, and 2021. Investors should note that this is an amendment, suggesting potential updates or clarifications to previously filed information, and a thorough review of the referenced exhibits and schedules is crucial for a comprehensive understanding of the company's financial position and performance. The limited information provided in the excerpt focuses on the documentation filed rather than detailed operational or financial performance metrics. Further details would be found within the full financial statements and exhibits referenced in Item 15 of the filing. Investors should exercise due diligence to access and analyze the complete report, including the detailed financial statements for the specified years, to ascertain any material changes or insights.

Financial Highlights

53 data points
Beta

Revenue

$2.46B

84.5% Gross Margin

Net Income

-$881.71M

-35.9% Net Margin

EPS (Diluted)

$-0.65

Total Assets

$5.81B

Cash & Equivalents

$3.19B

Free Cash Flow

-$1.72B

Financial Statements
Beta
Revenue$2.46B
Gross Profit$2.08B
R&D Expenses$1.78B
SG&A Expenses$1.51B
Operating Expenses$3.29B
Operating Income-$1.21B
Interest Expense$20.80M
Net Income-$881.71M
EPS (Basic)$-0.65
EPS (Diluted)$-0.65
Shares Outstanding (Basic)1.36B
Shares Outstanding (Diluted)1.36B

Key Highlights

  • 1Filing is an Annual Report Amendment (10-K/A) for BeOne Medicines Ltd. (ONC) as of December 31, 2023, filed January 8, 2025.
  • 2The amendment primarily concerns Item 15: Exhibits and Financial Statement Schedules.
  • 3Includes Financial Statement Schedule I for the parent company, covering fiscal years 2023, 2022, and 2021.
  • 4Investors should review the referenced exhibits and detailed financial statements for a complete understanding.
  • 5This filing may contain updates or clarifications to previously submitted financial information.
  • 6The excerpt does not provide specific operational or detailed financial performance data, necessitating a review of the full filing.
  • 7Focus is on the reporting of financial statements and exhibits, not on new business developments or strategic shifts.

Frequently Asked Questions

This filing is an Amendment to BeOne Medicines Ltd.'s Annual Report (10-K/A). Its primary purpose, based on the excerpt, is to provide updated or additional information concerning Exhibits and Financial Statement Schedules, specifically including the parent company's financial statements (Schedule I) for the years 2023, 2022, and 2021.

The provided excerpt from Item 15 indicates that detailed financial statements for the parent company for the years 2023, 2022, and 2021 are filed as Schedule I. Investors will need to access and review these specific financial statements and the referenced exhibits within the complete 10-K/A filing to obtain detailed financial performance information.

Based on the limited information provided in the excerpt, this filing appears to be focused on the submission of financial statements and exhibits. It does not explicitly mention new business strategies or significant operational changes. Investors should consult the full report, particularly any Management's Discussion and Analysis section (if included in the complete filing), for such strategic details.

An amendment (10-K/A) is filed when a company needs to correct or supplement information previously submitted in a standard filing. This suggests that BeOne Medicines Ltd. is either correcting an error, providing omitted information, or adding details to their previously filed annual report. Investors should pay close attention to what has been amended or added compared to the original filing.